Bio-Techne Toekomstige groei
Future criteriumcontroles 3/6
Bio-Techne zal naar verwachting groeien in winst en omzet met respectievelijk 21.2% en 8.8% per jaar. De winst per aandeel zal naar verwachting groeien met 20.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.8% zijn.
Belangrijke informatie
21.2%
Groei van de winst
20.3%
Groei van de winst per aandeel
| Life Sciences winstgroei | 18.3% |
| Inkomstengroei | 8.8% |
| Toekomstig rendement op eigen vermogen | 13.8% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 31 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings
Nov 06
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching
Sep 11Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings
Aug 24When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jun 09Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 6/30/2027 | 1,487 | 325 | 720 | 605 | 8 |
| 6/30/2026 | 1,338 | 261 | 371 | 421 | 13 |
| 6/30/2025 | 1,223 | 198 | 295 | 347 | 14 |
| 9/30/2024 | 1,172 | 151 | 245 | 303 | N/A |
| 6/30/2024 | 1,159 | 168 | 236 | 299 | N/A |
| 3/31/2024 | 1,154 | 203 | 251 | 307 | N/A |
| 12/31/2023 | 1,145 | 224 | 225 | 276 | N/A |
| 9/30/2023 | 1,144 | 247 | 215 | 258 | N/A |
| 6/30/2023 | 1,137 | 285 | 216 | 254 | N/A |
| 3/31/2023 | 1,124 | 271 | 233 | 274 | N/A |
| 12/31/2022 | 1,120 | 262 | 252 | 296 | N/A |
| 9/30/2022 | 1,118 | 292 | 285 | 333 | N/A |
| 6/30/2022 | 1,106 | 272 | 280 | 325 | N/A |
| 3/31/2022 | 1,076 | 225 | 302 | 345 | N/A |
| 12/31/2021 | 1,030 | 210 | 308 | 346 | N/A |
| 9/30/2021 | 985 | 177 | 295 | 335 | N/A |
| 6/30/2021 | 931 | 140 | 308 | 352 | N/A |
| 3/31/2021 | 848 | 184 | 225 | 275 | N/A |
| 12/31/2020 | 799 | 175 | 201 | 250 | N/A |
| 9/30/2020 | 760 | 248 | 179 | 231 | N/A |
| 6/30/2020 | 739 | 229 | 153 | 205 | N/A |
| 3/31/2020 | 755 | 187 | 170 | 216 | N/A |
| 12/31/2019 | 745 | 195 | 165 | 207 | N/A |
| 9/30/2019 | 734 | 93 | 151 | 183 | N/A |
| 6/30/2019 | 714 | 96 | 156 | 182 | N/A |
| 3/31/2019 | 703 | 121 | 171 | 191 | N/A |
| 12/31/2018 | 682 | 96 | 154 | 173 | N/A |
| 9/30/2018 | 661 | 128 | 145 | 165 | N/A |
| 6/30/2018 | 643 | 126 | N/A | 170 | N/A |
| 3/31/2018 | 619 | 112 | N/A | 156 | N/A |
| 12/31/2017 | 599 | 114 | N/A | 160 | N/A |
| 9/30/2017 | 577 | 73 | N/A | 162 | N/A |
| 6/30/2017 | 563 | 76 | N/A | 144 | N/A |
| 3/31/2017 | 541 | 74 | N/A | 129 | N/A |
| 12/31/2016 | 528 | 82 | N/A | 141 | N/A |
| 9/30/2016 | 517 | 101 | N/A | 138 | N/A |
| 6/30/2016 | 499 | 104 | N/A | 144 | N/A |
| 3/31/2016 | 482 | 105 | N/A | 145 | N/A |
| 12/31/2015 | 465 | 99 | N/A | 138 | N/A |
| 9/30/2015 | 456 | 107 | N/A | 135 | N/A |
| 6/30/2015 | 452 | 108 | N/A | 139 | N/A |
| 3/31/2015 | 427 | 108 | N/A | 140 | N/A |
| 12/31/2014 | 408 | 116 | N/A | 144 | N/A |
| 9/30/2014 | 380 | 107 | N/A | 140 | N/A |
| 6/30/2014 | 358 | 111 | N/A | 137 | N/A |
| 3/31/2014 | 345 | 113 | N/A | 129 | N/A |
| 12/31/2013 | 330 | 114 | N/A | 127 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei TECH ( 21.2% per jaar) ligt boven de spaarquote ( 2.6% ).
Winst versus markt: De winst van TECH ( 21.2% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).
Hoge groeiwinsten: De winst van TECH zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van TECH ( 8.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van TECH ( 8.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen TECH zal naar verwachting over 3 jaar laag zijn ( 13.8 %).